摘要：目的 观察哌拉西林/他唑巴坦治疗恶性血液病化疗后粒细胞减少伴发热的疗效及不良反应.方法 回顾性分析本院收治的86例恶性血液病化疗后粒细胞减少伴发热患者的临床资料,其中34例接受哌拉西林/他唑巴坦治疗,52例接受美罗培南治疗,两组均联合依替米星.结果 哌拉西林/他唑巴坦组和美罗培南组有效率分别为73.53%和80.77%(P＞0.05);两组不良反应均轻微,二重感染发生率分别为5.88%和15.38%(P＞0.05).结论 哌拉西林/他唑巴坦的疗效与美罗培南相似,二重感染发生率低,可作为恶性血液病粒细胞减少患者合并感染的一线经验性治疗. Abstract： Objective To evaluate the effect and safety of piperacillin-tazobactam on febrile neutropenic patients with hematological malignancy. Methods A total of 34 patients received piperacillin-tazobactam 4.5 g every 8 hours and 52 cases received meiluopeinan 0.5 g every 6 hours. Etimicin was combined in both groups. Results Clinical responses between groups were comparable. The effective rate of piperacillin-tazobactam and meiluopeinan were 73.53% and 80.77% respectively (P＞0.05), the side effects were mild in both groups, but the superinfection was more common in meiluopeinan group (15.38%) than that in piperacillin-tazobactam (5.88%, P＞0.05). Conclusions Piperacillin-tazobactam is as effective as meiluopeinan with fewer superinfection. It seems to be a good choice as initial empiric therapy for febrile neutropenic patients with malignant hematological diseases.

关键词：哌拉西林 他唑巴坦 经验性治疗 恶性血液病 化疗后 

单位：